Jun 13, 2020
VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients
Jun 13, 2020
EHA25Virtual: A Paradigm Shift for the Treatment of Newly Diagnosed Older Acute Myeloid Leukemia Patients
Jun 08, 2020
Neurelis Announces Rapid and Broad Payer Coverage of the Company's Flagship Product, VALTOCO® (Diazepam Nasal Spray)
May 20, 2020
Mitsubishi Tanabe Pharma America Announces Launch Of The JourneyMate Program, Offering Live Nurse Educational Phone Support For ALS Patients And Caregivers
May 19, 2020
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States
May 14, 2020
Tolero Pharmaceuticals Announces Expansion of the Zella 102 Study in Patients with Intermediate and High-Risk Myelodysplastic Syndromes (MDS)
May 14, 2020
SciMount announces FDA approval of SMP-100's IND application for the treatment of Irritable Bowel Syndrome
May 14, 2020
Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Presentation at 25th EHA Congress
May 07, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020
May 05, 2020
Mitsubishi Tanabe Pharma America Marks Third Anniversary Of FDA Approval And Reports More Than 5,000 Patients With ALS Treated With RADICAVA® (edaravone)
Mar 31, 2020
Bausch Health Announces Favorable Topline Results From Study Evaluating Investigative Formulation of Rifaximin SSD IR to Treat Overt Hepatic Encephalopathy
Mar 25, 2020
Apixaban (CAS 503612-47-3) Market Research Report 2020 - ResearchAndMarkets.com
Mar 23, 2020
AbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Mar 09, 2020
The irritable bowel syndrome treatment market was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026
Mar 02, 2020
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019 and Highlights Recent Corporate Updates
Mar 02, 2020
Neurelis Announces Commercial Availability of VALTOCO® (Diazepam Nasal Spray) for Seizure Cluster Rescue
Feb 17, 2020
Irritable Bowel Syndrome Treatment Market to Reach $2.01 Bn, Globally, by 2026 at 8.2% CAGR, Says Allied Market Research
Feb 13, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
Jan 14, 2020
ANI Announces Launch of Paliperidone Extended-Release Tablets
Jan 13, 2020
Neurelis Announces FDA Approval for Seizure Rescue Treatment VALTOCO® (Diazepam Nasal Spray) that Incorporates the Science of Intravail® for Consistent and Reliable Absorption